CCAP reports today with options positioning signalling more caution than the broader lending market warrants.
The clearest pre-earnings signal is in options. The put/call ratio jumped to 1.42 on May 13 — roughly 1.7 standard deviations above its 20-day average of 1.10. That is the most defensive options skew in several months, though it remains below the 52-week peak of 1.75, suggesting nerves rather than outright alarm. The move stands in contrast to a borrow market that looks anything but stressed: cost to borrow has eased to 0.61% from around 0.96% in early April, and availability remains ample. Short interest has ticked up about 7% over the past week to roughly 518,000 shares, but that is a small position in absolute terms and the ORTEX short score of 38 sits squarely in the middle of the range — no meaningful squeeze or pile-on dynamic.
Price action going into the print has been mixed. CCAP has recovered about 5% over the past month but given back nearly 5% this week, closing at $13.07. Peers have broadly softened too — CGBD fell nearly 7% on the week, NCDL dropped over 8%, while and held losses to around 4-5%. CCAP's relative underperformance is modest but real.
The analyst debate centres on credit quality. Bulls point to meaningful net portfolio growth in the prior quarter and a sharp decline in watchlist investments — from 3.1% to 1.2% of cost — as evidence the portfolio is stabilising. Bears flag the opposite trajectory for NAV, which fell $0.36 per share to $19.62 last quarter as operating earnings failed to fully cover the dividend, alongside a rise in non-accruals to 3.3% at cost. Keefe, Bruyette & Woods trimmed their target modestly to $15.00 in mid-April while holding an Outperform rating. Wells Fargo cut to $13.00 in February, barely above where the stock trades now. B. Riley initiated at Neutral with a $13.50 target in late March. The analyst community is split between cautious optimism and a wait-and-see posture — the consensus target of $15.75 implies meaningful upside from current levels, but the trend in target revisions has been persistently downward. Note that the $15.75 mean target is drawn from data through November 2025 and the recent targets from 2026 cluster closer to $13–$15.
Today's print is less about whether CCAP is growing its portfolio and more about whether non-accrual trends are stabilising and whether operating earnings can close the gap with dividend obligations — two questions that have driven the divergence between bulls and bears all year.
See the live data behind this article on ORTEX.
Open CCAP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
